By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Myriad Genetics announced after the close of the market on Wednesday that it has obtained an exclusive license to the RAD51C gene, which has been associated with an increased risk for hereditary breast and ovarian cancers.

The license from a consortium of German researchers gives Myriad the exclusive global rights, with co-exclusive rights in Germany, to provide commercial testing for the gene.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

NPR reports that Turkish high school students will no longer study evolution.

Researchers report they sequenced and identified plant species in an "al fresco" laboratory.

An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.

In PNAS this week: host contributors to typhoid fever risk, effects of obesity-related variants near TMEM18, and more.